SureTrader
Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Genetic Testing for Cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hlegweakreturns Member Profile
 
Followed By 1
Posts 448
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for ... "GlobeNewswire Inc." - 1/17/2018 8:00:00 AM
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Eval... "GlobeNewswire Inc." - 1/9/2018 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/8/2018 8:17:32 AM
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squa... "GlobeNewswire Inc." - 1/8/2018 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/2/2018 4:07:26 PM
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China "GlobeNewswire Inc." - 1/2/2018 8:00:00 AM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development "GlobeNewswire Inc." - 12/11/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/6/2017 2:08:10 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 12/6/2017 2:06:14 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/6/2017 1:58:14 PM
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors "GlobeNewswire Inc." - 12/6/2017 8:00:00 AM
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clini... "GlobeNewswire Inc." - 11/29/2017 8:00:00 AM
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor a... "GlobeNewswire Inc." - 11/27/2017 8:00:00 AM
Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference "GlobeNewswire Inc." - 11/10/2017 10:27:55 AM
Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences "GlobeNewswire Inc." - 11/9/2017 8:00:00 AM
Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results "GlobeNewswire Inc." - 11/8/2017 4:05:00 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 3:58:49 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2017 6:07:10 AM
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhi... "GlobeNewswire Inc." - 11/1/2017 9:18:26 AM
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017 "GlobeNewswire Inc." - 10/26/2017 8:00:00 AM
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study... "GlobeNewswire Inc." - 10/24/2017 8:00:00 AM
Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inh... "GlobeNewswire Inc." - 10/16/2017 7:00:00 AM
Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine "GlobeNewswire Inc." - 10/5/2017 7:00:00 AM
Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Prec... "GlobeNewswire Inc." - 9/21/2017 8:00:00 AM
Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection "GlobeNewswire Inc." - 9/18/2017 8:00:00 AM
hlegweakreturns   Friday, 10/18/13 06:04:49 AM
Re: None
Post # of 14158 
Genetic Testing for Cancer
Is evolving very quickly and many folks are getting into the business. And there is more than one in New Jersey. Roche is entering this market, and they are not alone. Yesterday Bloomberg had an article on Quest entering the Breast-Cancer Test Market that is currently dominated by Myriad. I don't think Roche has any interest in Quest, but they obviously are looking for expanding their genetic diagnostic capability going forward, as evidenced by the PACB deal, and another agreement with a smaller, and interesting player in this market. So here is the article if you have any interest in tangential developments:

"Quest Diagnostics Inc. (DGX), the biggest U.S. operator of medical labs, began yesterday to sell a test for two breast cancer genes, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.Quest will sell the most comprehensive version of its test for the BRCA1 and BRCA2 genes for $2,500, said Richard Bender, a consultant for the Madison, New Jersey-based company. The price compares with almost $3,400 that Medicare pays for the most comprehensive version of a test from Myriad.

Myriad held a U.S. monopoly over the BRCA tests until June, when the U.S. Supreme Court invalidated parts of its gene patents. Immediately afterward, Ambry Genetics Corp. and another closely held company said they were entering the BRCA market. Quest is the largest competitor to move into the field. Quest’s test “will certainly be comparable to if not better than the data provided by Myriad” in its ability to identify a harmful mutation, Bender said by telephone.
Quest’s incursion into the BRCA testing market sets up a potential legal battle with Myriad, which has various remaining patents on its tests. “We feel we offer a test that is the gold standard in quality,” Ronald Rogers, a Myriad spokesman, said in a phone interview." http://www.bloomberg.com/news/2013-10-16/interdigital-mattel-navistar-intellectual-property.html?cmpid=yhoo




Quest’s test “does not violate any valid BRCA patent that Myriad Genetics may assert,” Wendy Bost, a Quest spokeswoman, said in an e-mail.
Quest said in an Oct. 10 complaint filed in federal court in Santa Ana, California, that it believes Myriad will bring a patent-infringement lawsuit if it starts selling its BRCA test products.
Myriad hasn’t yet been served with Quest’s complaint, said Rogers. “Once we receive that, we will read through it and weigh our options,” he said.
The case is Quest Diagnostics Inc. v. Myriad Genetics Inc. (MYGN), 13-cv-01587, U.S. District Court, Central District of California (Santa Ana).


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist